Non-Enrolling and High-Enrolling Site Data
Applied Clinical Trials
Medidata Solutions
Site performance is a critical factor in the success of any clinical trial. Sponsors are continually looking for ways to better track site performance and minimize the number of sites that fail to enroll a patient. To that end, Medidata has tracked two metrics related to the performance of investigative sites, the percentages of both non-enrolling and high-enrolling sites. A non-enrolling site is a site that actively participated in a clinical trial but failed to recruit any patients.
Nearly one-third of sites performing clinical trials never enroll a single patient.
Non-enrolling sites contribute significantly to both study delays and unnecessary costs. Drawn from the more than 2,000 studies in the Medidata InsightsTM metric warehouse, the non-enrolling site performance metric shown in the graph illustrates that nearly one-third of sites performing clinical trials never enroll a single patient. While Asia Pacific is clearly the best performing geographic region at just more than 17%, in certain geographies the percentage is over 40%.
At tens of thousands of dollars in site initiation and maintenance costs per site, wouldn't it be nice to be able to eliminate or at least reduce the number of non-productive sites? What can be done to drive better site selection and performance? We'd love to hear your take on these results.
Please continue to stay tuned as we look further into Insights data throughout 2012.
—Medidata Solutions, www.mdsol.com
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
